Advertisement

The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol)

  • Jonathan K. Armstrong
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

Specific antibodies against poly(ethylene glycol) (anti-PEG) were induced in animals following exposure to PEG-conjugated proteins and particles, resulting in rapid clearance of PEG-conjugated agents. In humans, induction of anti-PEG was observed following exposure to a PEG-conjugated drug, and pre-existing anti-PEG was identified in over 25% the healthy population. In clinical studies, the presence of anti-PEG was strongly associated with rapid clearance of PEG-asparaginase and PEG-uricase. PEGylation of therapeutic agents will continue to be of significant value in medicine to reduce immunogenicity, antigenicity and toxicity as well as markedly reducing renal clearance, while maintaining drug efficacy. It is important to recognize that PEG itself may possess antigenic and immunogenic properties. Further comprehensive studies are warranted to fully elucidate the effect of anti-PEG on PEG-conjugated agents and if confirmed in a prospective trial, patients should be screened and monitored for anti-PEG, and strategies developed to overcome the potential negative effect of anti-PEG on drug clearance to improve the effectiveness of therapy.

Keywords

Rapid Clearance Severe Combine Immune Deficiency Rabbit Seron Patent Cooperation Treaty PEGylated Liposome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bailey FE, Koleske JV (eds) (1991) Alkylene oxides and their polymers. Marcel Dekker, New YorkGoogle Scholar
  2. 2.
    Bailey FE, Koleske JV (eds) (1976) Poly(ethylene oxide). Academic Press, New YorkGoogle Scholar
  3. 3.
    Pang SNJ (1993) Final report on the safety assessment of polyethylene glycols (PEGs) −6, −8, −32, −75, −150, −14M, −20M. J Am Coll Toxicol 12: 429–457Google Scholar
  4. 4.
    Fruijtier-Pölloth C (2005) Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicol 214: 1–38CrossRefGoogle Scholar
  5. 5.
    Abuchowski A, van Es T, Palczuk NC, Davis FF (1977) Alteration and immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252: 3578–3581PubMedGoogle Scholar
  6. 6.
    Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252: 3582–3586PubMedGoogle Scholar
  7. 7.
    Pasut G, Sergi M, Veronese FM (2008) Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 60: 69–78CrossRefPubMedGoogle Scholar
  8. 8.
    Graham ML (2003) Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 55: 1293–1302CrossRefPubMedGoogle Scholar
  9. 9.
    Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI (2004) Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 10: 5335–5341CrossRefPubMedGoogle Scholar
  10. 10.
    Matthews SJ, McCoy C (2004) Peginterferon alfa-2a: A review of approved and investigational uses. Clin Therapeut 26: 991–1025CrossRefGoogle Scholar
  11. 11.
    Koslowski A, Charles SA, Harris JM (2001) Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15: 419–429CrossRefGoogle Scholar
  12. 12.
    Luxon BA, Grace M, Brassard D, Bordens R (2002) Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 24: 1363–1383CrossRefPubMedGoogle Scholar
  13. 13.
    Stathopoulos GP, Dimou E, Stathopoulos J, Xynotroulas J (2005) Therapeutic administration of pegfilgrastim instead of prophylatic use. Anticancer Res 25: 2445–2448PubMedGoogle Scholar
  14. 14.
    Molineux G (2004) The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®). Curr Pharm Des 10: 1235–1244CrossRefPubMedGoogle Scholar
  15. 15.
    Piedmonte DM, Treuheit MJ (2008) Formulation of Neulasta® (pegfilgrastim). Adv Drug Deliv Rev 60: 50–58CrossRefPubMedGoogle Scholar
  16. 16.
    Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Market ML, Kobayashi RH, Abuchowski A (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol modified adenosine deaminase. New Engl J Med 316: 589–596PubMedCrossRefGoogle Scholar
  17. 17.
    Hershfield MS (1997) Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEG-ADA). In: JM Harris, S Zalipsky (eds): Poly(ethylene glycol): chemistry and biological applications. American Chemical Society, Washington DC, 145–154CrossRefGoogle Scholar
  18. 18.
    Greenwald RB, Choe YH, McGuire J, Conover CD (2003) Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 55: 217–250CrossRefPubMedGoogle Scholar
  19. 19.
    Francis GE, Fisher D, Delgado C, Malik F, Gardiner A, Neale D (1998) PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol 68: 1–18CrossRefPubMedGoogle Scholar
  20. 20.
    Delgado C, Francis GE, Fisher D (1992) The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 9: 249–304PubMedGoogle Scholar
  21. 21.
    Molineux G (2002) Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 28(suppl A): 13–16CrossRefPubMedGoogle Scholar
  22. 22.
    Veronese FM, Morpurgo M (1999) Bioconjugation in pharmaceutical chemistry. Farmaco 54: 497–516CrossRefPubMedGoogle Scholar
  23. 23.
    Monfardini C, Veronese FM (1998) Stabilization of substances in circulation. Bioconj Chem 9: 418–450CrossRefGoogle Scholar
  24. 24.
    Veronese FM, Caliceti P, Schiavon O, Sergi M (2002) Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 54: 587–606CrossRefPubMedGoogle Scholar
  25. 25.
    Hinds KD, Kim SW (2002) Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 54: 505–530CrossRefPubMedGoogle Scholar
  26. 26.
    Roberts MJ, Harris MJ (1998) Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J Pharm Sci 87: 1440–1445CrossRefPubMedGoogle Scholar
  27. 27.
    Gaberc-Porekar V, Zore I, Podobnik B, Menart V (2008) Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opinin Drug Discov Develop 11: 242–250Google Scholar
  28. 28.
    Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 54: 531–545CrossRefPubMedGoogle Scholar
  29. 29.
    Bjorkholm M, Fagrell B, Przybelski R, Winslow N, Young M, Winslow RM (2005) A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica 90: 505–515PubMedGoogle Scholar
  30. 30.
    Hinds KD, Kim SW (2002) Affects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 54: 505–530CrossRefPubMedGoogle Scholar
  31. 31.
    Parveen S, Sahoo SK (2006) Nanomedicine: Clinical application of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 45: 965–988CrossRefPubMedGoogle Scholar
  32. 32.
    van Vlerken LE, Vyas TK, Amiji MM (2007) Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 24: 1405–1414CrossRefPubMedGoogle Scholar
  33. 33.
    Dreborg S, Åkerblom E (1990) Immunotherapy with monomethoxypolyethylene glycol modified allergens. Crit Rev Ther Drug Carrier Syst 6: 315–365PubMedGoogle Scholar
  34. 34.
    Fishburn CS (2008) The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 97: 4167–4183CrossRefPubMedGoogle Scholar
  35. 35.
    Richter AW, Åkerblom E (1984) Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 74: 36–39CrossRefPubMedGoogle Scholar
  36. 36.
    Richter AW, Åkerblom E (1983) Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 74: 124–131CrossRefGoogle Scholar
  37. 37.
    Martinez AL, Sherman MR, Saifer MGP, Williams LD (2004) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof. Patent Cooperation Treaty WO/2004/030617Google Scholar
  38. 38.
    Armstrong JK, Fisher TC (2008) Poly(ethylene glycol) anti-body detection assays and kits for performing thereof. Patent Cooperation Treaty WO/2008/063663Google Scholar
  39. 39.
    Garratty G (2008) Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang 94: 87–95PubMedGoogle Scholar
  40. 40.
    Armstrong JK, Meiselman HJ, Wenby RB, Fisher TC (2003) In vivo survival of poly(ethylene glycol)-coated red blood cells in the rabbit. Blood 102: 94ACrossRefGoogle Scholar
  41. 41.
    Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR (1999) Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconj Chem 10: 520–528CrossRefGoogle Scholar
  42. 42.
    Cheng TL, Cheng CM, Chen BM, Tsao DA, Chuang KH, Hsiao SW, Lin YH, Roffler SR (2005) Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes and nanoparticles. Bioconj Chem 16: 1225–1231CrossRefGoogle Scholar
  43. 43.
    Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR (2000) Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconj Chem 11: 258–266CrossRefGoogle Scholar
  44. 44.
    Dams ETM, Laverman P, Oyen WJG, Storm G, Scherphof GL, van der Meer JWM, Corstens FHM, Boerman OC (2000) Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292: 1071–1079PubMedGoogle Scholar
  45. 45.
    Judge A, McClintock K, Phelps JR, MacLachlan I (2006) Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 13: 328–337CrossRefPubMedGoogle Scholar
  46. 46.
    Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ (2005) Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther 312: 1020–1026CrossRefPubMedGoogle Scholar
  47. 47.
    Laverman P, Carstens MG, Boerman OC, Dams ETM, Oyen WJG, van Rooijen N, Corstens FHM, Storm G (2001) Factors affecting accelerated blood clearance of polyethylene glycol-liposomes upon repeat injection. J Pharmacol Exp Ther 298: 607–612PubMedGoogle Scholar
  48. 48.
    Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF (2005) Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett 10: 37–47PubMedGoogle Scholar
  49. 49.
    Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H (2003) Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release 88: 35–42CrossRefPubMedGoogle Scholar
  50. 50.
    Ishida T, Masuda K, Ichikawa T, Ichihara M, Irimura K, Kiwada H (2003) Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm 255: 167–174CrossRefPubMedGoogle Scholar
  51. 51.
    Ishida T, Kiwada H (2008) Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354: 56–62CrossRefPubMedGoogle Scholar
  52. 52.
    Ishida T, Wang XY, Shimizu T, Nawat K, Kiwada H (2007) PEGylated liposomes elicit an anti-PEG IgM reponse in a T cell-independent manner. J Control Release 122: 349–355CrossRefPubMedGoogle Scholar
  53. 53.
    Ishida T, Kashima S, Kiwada H (2008) The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J Control Release 126: 162–165PubMedGoogle Scholar
  54. 54.
    Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS (2006) Control of hyperuricemia in subjects with refractory gout, and induction of an antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8: R12CrossRefPubMedGoogle Scholar
  55. 55.
    Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS (2007) Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 56: 1021–1028 Erratum in: (2007) Arthritis Rheum 56: 1370CrossRefPubMedGoogle Scholar
  56. 56.
    Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G (2007) Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic patients. Cancer 110: 103–111CrossRefPubMedGoogle Scholar
  57. 57.
    Amgen, Annual Financial Report (2007) http://www.amgen.com/pdfs/Investors_2007_AnnualReport.pdfGoogle Scholar
  58. 58.
    Schering-Plough, Annual Financial Report (2007) http://thomson.mobular.net/thomson/7/2707/3250/Google Scholar
  59. 59.
    Roche Pharmaceuticals, Annual Financial Report (2007) http://www.roche.com/gb07e04.pdfGoogle Scholar
  60. 60.
    Enzon, Annual Financial Report (2007) http://investor.enzon.com/annuals.cfmGoogle Scholar
  61. 61.
    OSI Pharmaceuticals, Annual Financial Report (2007) http://media.corporate-ir.net/media_files/irol/70/70584/2007_OSIP_Annual_Report.pdfGoogle Scholar
  62. 62.
    Caliceti P, Schiavon O, Veronese FM (2001) Immunological properties of uricase conjugated to neutral soluble polymers. Bionconj Chem 12: 515–522CrossRefGoogle Scholar
  63. 63.
    Roberts MJ, Green ME, Baker MR (2002) Antibodies specific for poly(ethylene glycol). Patent Cooperation Treaty WO/2002/094853Google Scholar
  64. 64.
    Sherman MR, Saifer MGP, Perez-Ruiz F (2008) PEG-uricase in the management of gout and hyperuricemia. Adv Drug Deliv Rev 60: 59–68CrossRefPubMedGoogle Scholar
  65. 65.
    Li WM, Bally MB, Schutzde-Redelmeier MP (2002) Enhanced immune response to T-independent antigen using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20: 148–157CrossRefGoogle Scholar
  66. 66.
    Boeckler C, Dautel D, Schelté P, Frisch B, Wachsmann D, Klein JP, Schuber F (1999) Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes. Eur J Immunol 29: 2297–2308CrossRefPubMedGoogle Scholar
  67. 67.
    de Jong S, Chikh G, Sekirov L, Raney S, Semple S, Klimuk S, Yuan N, Hope M, Cullis P, Tarn Y (2007) Encapsulation in liposomal nanoparticles enhances the immunstimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother 56: 1251–1264CrossRefPubMedGoogle Scholar
  68. 68.
    O’Hagan DT, Singh M (2003) Microparticles as vaccine adjuvants and delivery systems. Exp Rev Vaccines 2: 269–283CrossRefGoogle Scholar
  69. 69.
    Ishida T, Ichihara M, Wang XY, Kiwada H (2006) Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release 115: 243–250CrossRefPubMedGoogle Scholar
  70. 70.
    Armstrong JK, Leger R, Wenby RB, Meiselman HJ, Garratty G, Fisher TC (2003) Occurrence of an antibody to poly(ethylene glycol) in normal donors. Blood 102: 556AGoogle Scholar
  71. 71.
    General laboratory methods (1999) In: Vengelen-Tyler V (ed.): AABB Technical Manual (13th edition). American Association of Blood Banks, Bethesda MD, 646Google Scholar
  72. 72.
    Fisher TC, Armstrong JK, Wenby RW, Meisleman HJ, Leger R, Garratty G (2003) Isolation and identification of a human antibody to poly(ethylene glycol). Blood 102: 559AGoogle Scholar
  73. 73.
    Schick MJ (ed.) (1967) Nonionic surfactants. Marcel Dekker, New YorkGoogle Scholar
  74. 74.
    Smyth HF, Carpenter CP, Shaffer CB (1947) The toxicity of high molecular weight polyethylene glycols; chronic oral and parenteral administration. J Am Pharm Assoc 36: 157–160Google Scholar
  75. 75.
    Olser BL, Olser M (1957) Nutritional studies on rats on diets containing high levels of partial ester emulsifiers: IV Mortality and post mortem pathology; general conclusions. J. Nutrition 61: 235–252Google Scholar
  76. 76.
    Hooker E (2004) Final report on amended safety assessment of PEG-5, −10, −16, −25, −30 and −40 soy sterol. Int J Toxicol 23: 23–47CrossRefGoogle Scholar
  77. 77.
    Shaffer CB, Critchfield FH, Carpenter CP (1948) Renal excretion and volume distribution of some polyethylene glycols in the dog. Am J Physiol 151: 93–99Google Scholar
  78. 78.
    Shaffer CB, Critchfield FH (1947) The absorption and excretion of the solid polyethylene glycols (“Carbowax” compounds). J Am Pharm Assoc 36: 152–157Google Scholar
  79. 79.
    Yamaoka T, Tabata Y, Ikada Y (1994) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration in mice. J Pharm Sci 83: 601–606CrossRefPubMedGoogle Scholar
  80. 80.
    Yamaoka T, Tabata Y, Ikada Y (1995) Fate of water-soluble polymers administered via different routes. J Pharm Sci 84: 349–354CrossRefPubMedGoogle Scholar
  81. 81.
    Danielson GK, Dubilier LD, Bryant LR (1970) Use of Pluronic F-68 to diminish fat emboli and hemolysis during cardiopulmonary bypass. J Thorac Cardiovasc Surg 59: 178–184PubMedGoogle Scholar
  82. 82.
    Schaer GL, Spaccavento LJ, Browne KF, Krueger KA, Krichbaum D, Phelan JM, Fletcher WO, Grines CL, Edwards S, Jolly MK et al. (1996) Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, doubleblind, placebo-controlled trial. Circulation 94: 298–307PubMedGoogle Scholar
  83. 83.
    Grindel JM, Jaworski, T, Emanuele RM, Culbreth P (2002) Pharmacokinetics of a novel surfaceactive agent, purified poloxamer 188, in rat, rabbit, dog and man. Biopharmaceut Drug Dispos 23: 87–103CrossRefGoogle Scholar
  84. 84.
    Willcox ML, Newman MM, Paton BC (1978) A study of labeled Pluronic F-68 after intravenous administration into the dog. J Surg Res 25: 349–356CrossRefPubMedGoogle Scholar
  85. 85.
    Wang ZYJ, Stern IJ (1975) Disposition in rats of a polyoxypropylene-polyoxyethylene copolymer used in plasma fractionation. Drug Metabol Dispos 3: 536–542Google Scholar
  86. 86.
    Jewell RC, Khor SP, Kisor DF, LaCroix KAK, Wargin WA (1997) Pharmacokinetics of RheothRx injection in healthy male volunteers J Pharm Sci 86: 808–812CrossRefPubMedGoogle Scholar
  87. 87.
    Yang BB, Lum PK, Hayashi MM, Roskos LK (2004) Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci 93: 1367–1373CrossRefPubMedGoogle Scholar
  88. 88.
    Asgeirsson D, Venturoli D, Fries D, Rippe B, Rippe C (2007) Glomerular sieving of three neutral polysaccharides, polyethylene oxide and bikunin in rat. Effects of molecular size and conformation. Acta Physiol 191: 237–246CrossRefGoogle Scholar
  89. 89.
    Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D (2007) PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35: 9–16CrossRefPubMedGoogle Scholar
  90. 90.
    Fusco S, Borzacchiello A, Netti PA (2006) Perspectives on: PEO-PPO-PEO triblock copolymers and their biomedical applications. J Bioact Compat Polymers 21: 149–164CrossRefGoogle Scholar
  91. 91.
    Landsteiner K (1924) Experiments on anaphylaxis to azoproteins. J Exp Med 39: 631–637CrossRefPubMedGoogle Scholar
  92. 92.
    Tsai NM, Cheng TL, Roffler SR (2001) Sensitive measurement of polyethylene glycol modified proteins. BioTecniques 30: 396–402Google Scholar
  93. 93.
    Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, Parkman R, Weinberg K, Kohn DB (2005) Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol 17: 133–143CrossRefGoogle Scholar
  94. 94.
    Apostolidou E, Swords R, Alvarado Y, Giles FJ (2007) Treatment of acute lymphoblastic leukaemia: A new era. Drugs 67: 2153–2171CrossRefPubMedGoogle Scholar
  95. 95.
    Avramis VI, Tiwari PN (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed 1: 241–254Google Scholar
  96. 96.
    Kemmer N, Neff GW (2007) Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int 27: 1297–1310PubMedGoogle Scholar
  97. 97.
    Tydén G, Kumlien G, Efvergren M (2007) Present techniques for antibody removal. Transplantation 84: S27–S29CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2009

Authors and Affiliations

  • Jonathan K. Armstrong
    • 1
  1. 1.Department of Physiology and Biophysics, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations